
|Podcasts|September 24, 2021
Dr. Sarah Faris on taking precautions when prescribing postoperative opioids
Author(s)Urology Times staff
“Opioids are opioids…they can lead to long-term usage regardless of their FDA class. We really need to be good stewards for our patients,” says Sarah F. Faris, MD.
Advertisement
In this episode, Urology Times® Managing Editor Ben Saylor spoke with Sarah F. Faris, MD. She discusses the recent Urology study, “Persistent Opioid Usage After Urologic Intervention and the Impact of Tramadol,” and how clinicians need to take precaution when prescribing opioids for postoperative care. Faris is an associate professor of surgery at the University of Chicago, Illinois.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












